Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (25870)	9/29/1998 7:47:00 PM
From: RXGOLF	Read Replies (1) \| Respond to of 32384

I was about to agree with D.Lu, when I read your BUYOUT post. Are you merely making a hypothesis like so many thoughts on these boards, or do you Henry, feel that this is the motive behind todays move? All ears, Greg

To: Henry Niman who wrote (25870)	9/29/1998 7:52:00 PM
From: Arthur Radley	Read Replies (4) \| Respond to of 32384

Henry and others: With this buy-out clause with Elan, does it not bother anyone that here LNGD has had an ongoing working relationship with many of the major drug companies and NOW they strike such a deal with a totally new entity. In this deal they take on another penny-ante drug. What will make or break LGND IMO is Targretin. My question is why wouldn't one of these original companies working with LGND and with LGND's discoveries, and having inside information on LGND's potential, why would not one of them strike this deal with LGND. IMO it wasn't the Elan compound that was integral to this deal. Is LGND's mode of operation always to look for the next "fool" to keep them going? Just wondering, because the market apparently didn't like this further dilution and you can add me to that crowd.